Human-cl-rhFVIII in Previously Untreated Patients

Status: Recruiting
Phase: Phase 3
DFCI Protocol ID:

Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Ellis Neufeld, MD, PhD, Brigham and Women's Hospital

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria:

  -  Male patients

  -  Severe Hemophilia A (FVIII:C <1%)

  -  No previous treatment with with FVIII concentrates or other blood prodcuts containing

Exclusion Criteria:

  -  Diagnosis with a coagulation disorder other than Hemophilia A

  -  Severe liver or kidney disease

  -  Concomitant treatment with any systemic immunosuppressive drug

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.